Clinical Trials
Soligenix's HyBryte Therapy Shows Positive Safety Profile in Phase 3 CTCL Trial
Soligenix's HyBryte therapy demonstrated a positive safety profile in its ongoing Phase 3 FLASH2 study for cutaneous T-cell lymphoma, maintaining progress toward potential regulatory approval and commercialization as a first-line treatment option.
Stanford Study Shows Pulsed Shortwave Therapy Provides Sustained Pain Relief for Thumb Arthritis
A Stanford University clinical trial demonstrates that pulsed shortwave therapy offers lasting pain relief for thumb arthritis, potentially providing a safe, drug-free alternative to current limited treatment options for millions of affected adults.
Northwest Battle Buddies to Celebrate 300th Service Dog Team as Study Confirms PTSD Treatment Benefits
Northwest Battle Buddies' milestone of pairing 300 service dogs with combat veterans comes as a landmark study validates the significant therapeutic impact these dogs provide in reducing PTSD symptoms and improving veterans' quality of life.
NRx Pharmaceuticals to Present Depression Treatment Advancements at Noble Capital Markets Conference
NRx Pharmaceuticals will present its innovative depression treatments including a low-dose D-Cycloserine product that enhances Transcranial Magnetic Stimulation effectiveness and discuss expanded clinical operations and VA collaborations for treating suicidal depression and PTSD.
DGE to Host 5th Investigator-Initiated Trials Summit in Philadelphia, Addressing Clinical Research Challenges
The upcoming 5th Investigator-Initiated Trials Summit in Philadelphia brings together life sciences professionals to address critical challenges in clinical research programs, highlighting the importance of collaborative solutions in advancing medical innovation.
Quantum BioPharma Advances Multiple Sclerosis Treatment Toward Clinical Trials
Quantum BioPharma has received final toxicity reports for its Lucid-MS drug candidate, clearing a critical regulatory hurdle toward Phase 2 clinical trials for treating multiple sclerosis by targeting demyelination.
Sapu Nano Receives Australian Ethics Approval for Breast Cancer Drug Trial
Sapu Nano's Sapu003, an injectable form of Everolimus using proprietary nanoparticle technology, has received HREC approval for human clinical trials in Australia, potentially offering more effective breast cancer treatment through improved drug delivery.
Quantum BioPharma Appoints Leading MS Expert Dr. Jack Antel as Clinical Advisor for Lucid-MS Development
Quantum BioPharma has strengthened its multiple sclerosis program by appointing renowned neurologist Dr. Jack Antel to guide the clinical development of Lucid-21-302 as the investigational drug advances toward Phase 2 trials.
NYU's Judith Hochman to Receive 2025 Research Achievement Award for Transformative Cardiology Research
Dr. Judith Hochman's recognition by the American Heart Association highlights her pivotal clinical trials that have reshaped global cardiology guidelines and improved patient outcomes in ischemic heart disease.
FDA Guidance Accelerates Lantern Pharma's Pediatric Brain Cancer Therapy Development
Lantern Pharma received FDA guidance that will help advance its LP-184/STAR-001 therapy for rare pediatric brain cancers toward clinical trials planned for 2026, representing significant progress in treating conditions with limited options.
Soligenix Expands European Medical Advisory Board to Advance Cutaneous T-Cell Lymphoma Treatment
Soligenix Inc. has expanded its European Medical Advisory Board to guide the confirmatory Phase 3 trial of HyBryte for early-stage cutaneous T-cell lymphoma, strengthening European engagement ahead of potential commercialization of this novel photodynamic therapy.
Tonix Pharmaceuticals Advances TNX-2900 for Prader-Willi Syndrome Into Phase 2 Clinical Trial
Tonix Pharmaceuticals has received FDA clearance to begin Phase 2 trials for TNX-2900, a potential treatment for Prader-Willi syndrome, marking significant progress for a rare genetic disorder that causes life-threatening childhood obesity.
GeoVax Labs Secures $2.5 Million in Registered Direct Offering to Advance Clinical Programs
GeoVax Labs has raised $2.5 million through a registered direct offering to fund clinical development of its COVID-19 vaccine candidates and oncology therapies, positioning the company to advance multiple late-stage clinical trials.
Soligenix Advances Psoriasis Treatment Trial with Promising Early Results
Soligenix is progressing its SGX302 psoriasis treatment through clinical trials, offering potential for a new therapeutic option for millions affected by the autoimmune skin condition.
hyperCORE International Strengthens Executive Team with New Vice President and Treasurer Appointments
hyperCORE International has appointed Jeffrey Smyth as Vice President and Olivia McIver as Treasurer to enhance governance and support strategic growth across its clinical trial site network.
Clene's CNM-Au8 Shows Promising Brain Energy Improvements in Multiple Sclerosis Patients
Clene Inc. presented positive trial results demonstrating that its investigational therapy CNM-Au8 significantly improved brain energy metabolism in multiple sclerosis patients, potentially offering a new approach to slowing disease progression by addressing underlying bioenergetic failure.
Annovis Bio Appoints Mark Guerin as CFO to Lead Financial Strategy During Critical Late-Stage Trials
Annovis Bio has appointed experienced financial executive Mark Guerin as Chief Financial Officer to guide the company's financial strategy as its lead drug candidate buntanetap advances through late-stage clinical trials for Alzheimer's and Parkinson's disease.
Soligenix Advances HyBryte Treatment for Cutaneous T-Cell Lymphoma with FLASH Trial Results
Soligenix is strengthening its position in CTCL treatment through promising results from its HyBryte FLASH studies, representing significant progress toward establishing a new standard of care in an underserved therapeutic area.
Cybin Advances Neuropsychiatry Pipeline with Key Clinical Milestones and Extended IP Protection
Cybin Inc. is progressing multiple late-stage clinical programs for mental health treatments, with upcoming data readouts and regulatory advancements that could significantly impact the neuropsychiatry treatment landscape.
Oncotelic's Joint Venture Sapu Nano Receives Approval for Phase 1 Trial of Injectable Everolimus for Breast Cancer
Sapu Nano's approval to begin Phase 1 clinical trials for an injectable version of Everolimus represents a potential breakthrough in breast cancer treatment by enabling full drug absorption compared to the oral version's limited 10% bioavailability.
GeoVax Expands Gedeptin Cancer Therapy Development to Additional Solid Tumor Types
GeoVax Labs is expanding its Gedeptin cancer therapy development to include triple negative breast cancer and cutaneous malignancies, building on checkpoint inhibitor momentum and KEYNOTE-689 results to potentially improve outcomes for broader solid tumor patients.
LabConnect and The Bracken Group Forge Strategic Partnership to Enhance Radiopharmaceutical Trial Support
LabConnect's collaboration with The Bracken Group addresses the growing demand for specialized radiopharmaceutical expertise in clinical trials, positioning the partnership to better serve biotech and pharmaceutical companies developing targeted treatments and diagnostics.
Oncotelic Therapeutics CEO Outlines Key Clinical Milestones in BioMedWire Podcast Interview
Oncotelic Therapeutics CEO Dr. Vuong Trieu discussed the company's upcoming clinical and regulatory milestones in oncology and rare disease treatments during a recent podcast appearance, highlighting potential catalysts for investor attention.
GeoVax Reaffirms Commitment to Vaccine Safety Amid Development of GEO-CM04S1 for Immunocompromised Patients
GeoVax Labs emphasizes its evidence-based approach to vaccine safety and the advancement of GEO-CM04S1, a COVID-19 vaccine designed for vulnerable populations with weakened immune systems who respond poorly to current options.
Soligenix Advances Oral Mucositis Treatment SGX942 with Combined Clinical Data Analysis
Soligenix is leveraging positive phase 2 and 3 clinical data to design a second pivotal trial for SGX942, addressing the critical unmet medical need for oral mucositis treatment in cancer patients.
Lantern Pharma Completes Japan Enrollment in Phase 2 Trial for Never-Smoker Lung Cancer Treatment
Lantern Pharma has achieved targeted patient enrollment in Japan for its Phase 2 HARMONIC trial evaluating LP-300 in never-smoker non-small cell lung cancer patients, marking significant progress in addressing an underserved population with high unmet medical need.
Oncotelic Therapeutics Advances Late-Stage Oncology Pipeline Under Proven Leadership
Oncotelic Therapeutics is progressing multiple late-stage clinical programs in high-unmet-need oncology indications under CEO Dr. Vuong Trieu, whose track record with blockbuster cancer drugs positions the company for potential therapeutic breakthroughs.
Insilico Medicine CEO Outlines Path to Pharmaceutical Superintelligence as AI-Discovered Drugs Advance Through Clinical Trials
Insilico Medicine's CEO details how generative AI is transforming drug discovery, compressing development timelines and advancing multiple clinical programs, with the first fully AI-designed drugs potentially reaching patients within five to six years.
LabConnect Appoints Industry Veteran Bill Finger to Lead Global Strategic Services
LabConnect has appointed Bill Finger as Senior Vice President of Global Strategic Services, bringing over 25 years of diagnostics and clinical research expertise to enhance the company's capabilities in complex clinical trials.
GeoVax's CM04S1 Vaccine Shows Promise for Immunocompromised Patients in Phase 2 Trials
GeoVax Labs' next-generation COVID-19 vaccine candidate demonstrates superior immune responses in immunocompromised patients compared to mRNA vaccines, potentially addressing critical gaps in current vaccination strategies.